Phage Display Selection, Identification, and Characterization of Novel Pancreatic Cancer Targeting Peptides
Pancreatic cancer is characterized by a 5-year survival rate of 3%, in part due to inadequate detection methods. The small size of peptides offers advantages regarding molecular targeting. Thus, peptides may be used in detection of pancreatic cancer. Here, peptides that target pancreatic cancer cell...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-05-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/10/5/714 |
| _version_ | 1797568830146347008 |
|---|---|
| author | Mallika C. Asar April Franco Mette Soendergaard |
| author_facet | Mallika C. Asar April Franco Mette Soendergaard |
| author_sort | Mallika C. Asar |
| collection | DOAJ |
| description | Pancreatic cancer is characterized by a 5-year survival rate of 3%, in part due to inadequate detection methods. The small size of peptides offers advantages regarding molecular targeting. Thus, peptides may be used in detection of pancreatic cancer. Here, peptides that target pancreatic cancer cells were selected using phage display technology using a 15-mer fUSE5 library. Phage were pre-cleared against immortalized pancreatic cells (hTERT-HPNE), followed by selections against pancreatic cancer (Mia Paca-2) cells. Next-generation sequencing identified two peptides, MCA1 and MCA2, with a Log2 fold change (Mia Paca-2/ hTERT-HPNE) >1.5. Modified ELISA and fluorescent microscopy showed that both peptides bound significantly higher to Mia Paca-2 cells, and not to hTERT-HPNE, embryonic kidney (HEK 293), ovarian (SKOV-3) and prostate cancer (LNCaP) cell lines. Further characterization of MCA1 and MCA2 revealed EC<sub>50</sub> values of 16.11 µM (95% CI [9.69, 26.31 µM]) and 97.01 µM (95% CI [58.64, 166.30 µM]), respectively. Based on these results, MCA1 was selected for further studies. A competitive dose response assay demonstrated specific binding and an IC<sub>50</sub> value of 2.15 µM (95% CI [1.28, 3.62 µM]). Taken together, this study suggests that MCA1 may be used as a pancreatic cancer targeting ligand for detection of the disease. |
| first_indexed | 2024-03-10T20:02:39Z |
| format | Article |
| id | doaj.art-b3522351f7d44a51aba0b00d446c3991 |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-10T20:02:39Z |
| publishDate | 2020-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-b3522351f7d44a51aba0b00d446c39912023-11-19T23:30:02ZengMDPI AGBiomolecules2218-273X2020-05-0110571410.3390/biom10050714Phage Display Selection, Identification, and Characterization of Novel Pancreatic Cancer Targeting PeptidesMallika C. Asar0April Franco1Mette Soendergaard2Department of Chemistry, Western Illinois University, 1 University Circle, Macomb, IL 61455, USADepartment of Biological Sciences, Western Illinois University, 1 University Circle, Macomb, IL 61455, USADepartment of Chemistry, Western Illinois University, 1 University Circle, Macomb, IL 61455, USAPancreatic cancer is characterized by a 5-year survival rate of 3%, in part due to inadequate detection methods. The small size of peptides offers advantages regarding molecular targeting. Thus, peptides may be used in detection of pancreatic cancer. Here, peptides that target pancreatic cancer cells were selected using phage display technology using a 15-mer fUSE5 library. Phage were pre-cleared against immortalized pancreatic cells (hTERT-HPNE), followed by selections against pancreatic cancer (Mia Paca-2) cells. Next-generation sequencing identified two peptides, MCA1 and MCA2, with a Log2 fold change (Mia Paca-2/ hTERT-HPNE) >1.5. Modified ELISA and fluorescent microscopy showed that both peptides bound significantly higher to Mia Paca-2 cells, and not to hTERT-HPNE, embryonic kidney (HEK 293), ovarian (SKOV-3) and prostate cancer (LNCaP) cell lines. Further characterization of MCA1 and MCA2 revealed EC<sub>50</sub> values of 16.11 µM (95% CI [9.69, 26.31 µM]) and 97.01 µM (95% CI [58.64, 166.30 µM]), respectively. Based on these results, MCA1 was selected for further studies. A competitive dose response assay demonstrated specific binding and an IC<sub>50</sub> value of 2.15 µM (95% CI [1.28, 3.62 µM]). Taken together, this study suggests that MCA1 may be used as a pancreatic cancer targeting ligand for detection of the disease.https://www.mdpi.com/2218-273X/10/5/714pancreatic cancerphage displaypeptidesphagecancer targeting |
| spellingShingle | Mallika C. Asar April Franco Mette Soendergaard Phage Display Selection, Identification, and Characterization of Novel Pancreatic Cancer Targeting Peptides Biomolecules pancreatic cancer phage display peptides phage cancer targeting |
| title | Phage Display Selection, Identification, and Characterization of Novel Pancreatic Cancer Targeting Peptides |
| title_full | Phage Display Selection, Identification, and Characterization of Novel Pancreatic Cancer Targeting Peptides |
| title_fullStr | Phage Display Selection, Identification, and Characterization of Novel Pancreatic Cancer Targeting Peptides |
| title_full_unstemmed | Phage Display Selection, Identification, and Characterization of Novel Pancreatic Cancer Targeting Peptides |
| title_short | Phage Display Selection, Identification, and Characterization of Novel Pancreatic Cancer Targeting Peptides |
| title_sort | phage display selection identification and characterization of novel pancreatic cancer targeting peptides |
| topic | pancreatic cancer phage display peptides phage cancer targeting |
| url | https://www.mdpi.com/2218-273X/10/5/714 |
| work_keys_str_mv | AT mallikacasar phagedisplayselectionidentificationandcharacterizationofnovelpancreaticcancertargetingpeptides AT aprilfranco phagedisplayselectionidentificationandcharacterizationofnovelpancreaticcancertargetingpeptides AT mettesoendergaard phagedisplayselectionidentificationandcharacterizationofnovelpancreaticcancertargetingpeptides |